Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT02062203
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT02056392
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
AZD3293 Thorough QT Study in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT02040987
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
- Conditions
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 42
- Registration Number
- NCT02027454
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Moxifloxacin in Situ Gel to Treat Periodontal Pocket.
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Sri Hasanamba Dental College and Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT02016157
- Locations
- 🇮🇳
Sri Hasanamba Dental College & Hospital, Hassan, Karnataka, India
A Phase 1 QT Study in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 72
- Registration Number
- NCT01986894
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Effect of Glucose on QTc Interval in Type 1 Diabetes
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Richmond Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT01984827
- Locations
- 🇬🇧
Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 863
- Registration Number
- NCT01968733
Tafenoquine Thorough QTc Study in Healthy Subjects
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 260
- Registration Number
- NCT01928914
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Inje University
- Target Recruit Count
- 40
- Registration Number
- NCT01876316
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.